Other studies have reported improvements in insulin sensitivity and glycemia with myostatin inhibition primarily in obese and type 2 diabetes animal models(35, 36, 37) but also in type 1 diabetes animal models.(38) However, these animal studies utilized different models of diabetes and/or myostatin inhibition than the present study and that could explain the discrepancy in the findings relating to glycemic control. Here, MSTN is linked to type 2 diabetes mellitus.